147 related articles for article (PubMed ID: 23968157)
1. CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study.
Ross J; Sharma S; Winston J; Nunez M; Bottini G; Franceschi M; Scarpini E; Frigerio E; Fiorentini F; Fernandez M; Sivilia S; Giardino L; Calza L; Norris D; Cicirello H; Casula D; Imbimbo BP
Curr Alzheimer Res; 2013 Sep; 10(7):742-53. PubMed ID: 23968157
[TBL] [Abstract][Full Text] [Related]
2. CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo-Controlled Study.
Ross J; Sharma S; Winston J; Nunez M; Bottini G; Franceschi M; Scarpini E; Frigerio E; Fiorentini F; Fernandez M; Sivilia S; Giardin L; Calzà L; Norris D; Cicirello H; Casula D; Imbimbo B
Curr Alzheimer Res; 2013 Aug; ():. PubMed ID: 23952019
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects.
Imbimbo BP; Frigerio E; Breda M; Fiorentini F; Fernandez M; Sivilia S; Giardino L; Calzà L; Norris D; Casula D; Shenouda M
Alzheimer Dis Assoc Disord; 2013; 27(3):278-86. PubMed ID: 22922591
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents.
Imbimbo BP; Del Giudice E; Cenacchi V; Volta R; Villetti G; Facchinetti F; Riccardi B; Puccini P; Moretto N; Grassi F; Ottonello S; Leon A
Pharmacol Res; 2007 Apr; 55(4):318-28. PubMed ID: 17292621
[TBL] [Abstract][Full Text] [Related]
5. CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid.
Porrini V; Lanzillotta A; Branca C; Benarese M; Parrella E; Lorenzini L; Calzà L; Flaibani R; Spano PF; Imbimbo BP; Pizzi M
Neuroscience; 2015 Aug; 302():112-20. PubMed ID: 25450955
[TBL] [Abstract][Full Text] [Related]
6. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
[TBL] [Abstract][Full Text] [Related]
7. The γ-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice.
Balducci C; Mehdawy B; Mare L; Giuliani A; Lorenzini L; Sivilia S; Giardino L; Calzà L; Lanzillotta A; Sarnico I; Pizzi M; Usiello A; Viscomi AR; Ottonello S; Villetti G; Imbimbo BP; Nisticò G; Forloni G; Nisticò R
J Alzheimers Dis; 2011; 24(4):799-816. PubMed ID: 21321397
[TBL] [Abstract][Full Text] [Related]
8. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.
Imbimbo BP; Hutter-Paier B; Villetti G; Facchinetti F; Cenacchi V; Volta R; Lanzillotta A; Pizzi M; Windisch M
Br J Pharmacol; 2009 Mar; 156(6):982-93. PubMed ID: 19239474
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effect of CHF5074, a new γ-secretase modulator, in a mouse model of scrapie.
Poli G; Corda E; Lucchini B; Puricelli M; Martino PA; Dall'ara P; Villetti G; Bareggi SR; Corona C; Vallino Costassa E; Gazzuola P; Iulini B; Mazza M; Acutis P; Mantegazza P; Casalone C; Imbimbo BP
Prion; 2012; 6(1):62-72. PubMed ID: 22453180
[TBL] [Abstract][Full Text] [Related]
10. CHF5074 protects SH-SY5Y human neuronal-like cells from amyloidbeta 25-35 and tumor necrosis factor related apoptosis inducing ligand toxicity in vitro.
Ronsisvalle N; Di Benedetto G; Parenti C; Amoroso S; Bernardini R; Cantarella G
Curr Alzheimer Res; 2014; 11(7):714-24. PubMed ID: 24938499
[TBL] [Abstract][Full Text] [Related]
11. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
13. Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies.
Goel G; King T; Daveson AJ; Andrews JM; Krishnarajah J; Krause R; Brown GJE; Fogel R; Barish CF; Epstein R; Kinney TP; Miner PB; Tye-Din JA; Girardin A; Taavela J; Popp A; Sidney J; Mäki M; Goldstein KE; Griffin PH; Wang S; Dzuris JL; Williams LJ; Sette A; Xavier RJ; Sollid LM; Jabri B; Anderson RP
Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):479-493. PubMed ID: 28506538
[TBL] [Abstract][Full Text] [Related]
14. CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice.
Beggiato S; Giuliani A; Sivilia S; Lorenzini L; Antonelli T; Imbimbo BP; Giardino L; Calzà L; Ferraro L
Neuroscience; 2014 Apr; 266():13-22. PubMed ID: 24530449
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals.
Galasko DR; Graff-Radford N; May S; Hendrix S; Cottrell BA; Sagi SA; Mather G; Laughlin M; Zavitz KH; Swabb E; Golde TE; Murphy MP; Koo EH
Alzheimer Dis Assoc Disord; 2007; 21(4):292-9. PubMed ID: 18090435
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
[TBL] [Abstract][Full Text] [Related]
17. From the multifactorial nature of Alzheimer`s disease to multitarget therapy: the contribution of the translational approach.
Calzà L; Baldassarro VA; Giuliani A; Lorenzini L; Fernandez M; Mangano C; Sivilia S; Alessandri M; Gusciglio M; Torricella R; Giardino L
Curr Top Med Chem; 2013; 13(15):1843-52. PubMed ID: 23931439
[TBL] [Abstract][Full Text] [Related]
18. Glial activation and inflammation along the Alzheimer's disease continuum.
Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
[TBL] [Abstract][Full Text] [Related]
19. CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease.
Imbimbo BP; Giardino L; Sivilia S; Giuliani A; Gusciglio M; Pietrini V; Del Giudice E; D'Arrigo A; Leon A; Villetti G; Calzà L
J Alzheimers Dis; 2010; 20(1):159-73. PubMed ID: 20164581
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.
Scheltens P; Hallikainen M; Grimmer T; Duning T; Gouw AA; Teunissen CE; Wink AM; Maruff P; Harrison J; van Baal CM; Bruins S; Lues I; Prins ND
Alzheimers Res Ther; 2018 Oct; 10(1):107. PubMed ID: 30309389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
